May 27, 2015
A dendritic cell vaccine targeted at patient-specific neoantigens expanded the antitumor immune response in patients with melanoma, according to study results.
“Neoantigens are like flags on a cancer cell, calling attention to the immune system,” Beatriz M. Carreno, PhD, of the division of oncology at Washington University School of Medicine, said during a press conference. “In any one patient with melanoma, there can be hundreds of flags on tumors. The challenge presented to us was how to identify the unique flags that were more likely to elicit a strong immune response against the tumor.”